The Effect of Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread" With 80% Reduced Sucrose on Glucose Response of People With TID

Last updated: April 11, 2024
Sponsor: Rabin Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Mellitus, Type 1

Treatment

Active Control-Nutella hazelnut cocoa spread

Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread"

Clinical Study ID

NCT06334302
RMC0362-23ctil
  • Ages 18-35
  • All Genders

Study Summary

Omega Galil has developed a novel fatty sweetener that allows the use of up to 80% less sugar (particularly sucrose) and yet achieves a natural sweet flavor, using a novel technology of milling the natural sucrose crystals together with oil and thus creating a micro-suspension of sugar in oil or fat. The suspension increases the surface area of the sugar particles and thus a lower quantity of sugar is required in order to reach an enhanced perception of sweetness at the sweet taste receptors in the mouth. Omega Galil provides fatty food products that use up to 80% less sucrose, while tasting as sweet as regular sugar sweetened foods, with no aftertastes of sugar substitutes, and no chemical modifications or additives.

Postprandial glucose (PPG) excursions in Type 1 Diabetes happen mainly due to a delay in subcutaneous insulin absorption and action, but also among other factors, depend on the meal composition. The glycemic index (GI) ranks foods based on acute glycemic response over a 2-h period of 50 g of available carbohydrates (CHO) of a test food compared with the reference standard glucose. Glycemic Load (GL) is a GI-weighted measure of carbohydrate content, which estimates the impact of carbohydrate intake using the GI while taking into account the amount of carbohydrates that are eaten in a serving. Several studies have demonstrated differences in PPG after consumption of low versus high GI meals, with rapid glucose spikes following high GI meals . Helping people with T1D achieve a diet with a lower glycemic load can improve both their quality of life and their diabetes-associated complications.

The proposed randomized, double blind, cross-over, active control, clinical trial aims to:

  1. compare the glycemic response of T1D subjects to 20 grams of the O'Sweet sugar-reduced spread containing 8% sugar and a total of 1.6 grams of sucrose per meal, with their glycemic response to 20 grams of control Nutella spread, containing 56% sugar and a total of 11 grams sucrose per meal.

  2. compare the acceptance ("Not sweet enough, just right or too sweet") Labeled Magnitude score of O'Sweet compared to the control spread (Nutella).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • T1D patients with diabetes duration >1 year
  • 18-35 years of age
  • Normal weight (BMI 20- 30 kg/m2)
  • Non-smoker
  • Hemoglobin A1C <9%
  • Patient treated with Continuous Glucose Monitoring system (CGM's)

Exclusion

Exclusion Criteria:

  • Acute Upper Respiratory Tract Infection (URTI) within 2 weeks of enrollment
  • A gastro-intestinal condition that could disrupt intestinal absorption or motility,and thereby impair postprandial glucose absorption (e.g. diabetic gastroparesis,celiac disease, or malabsorption).
  • A chronic illness in the past 5 years, including among others inflammatory, metabolic,neoplastic, and congenital disease.
  • Use of medications other than insulin (e.g. Antibiotics/antifungal, analgesics) duringthe study and 2 weeks before enrollment;
  • Neuro-psychiatric disorders
  • Known food allergies or intolerances
  • Self-reported sinus, taste or smell dysfunction
  • Pregnant or lactating women

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Active Control-Nutella hazelnut cocoa spread
Phase:
Study Start date:
March 25, 2024
Estimated Completion Date:
April 25, 2024

Connect with a study center

  • Schneider Children Medical Center of Israel

    Petach-Tikva,
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.